Showing results (551-560 of 6,499) with videos related to

Sort By:
Pageof 650
Cancer Immunology, Immunotherapy : CII|January 1, 1983
Immunotherapy of Lewis lung carcinoma with hydrosoluble peptidoglycan monomer (PGM)G Sava, T Giraldi, J Tomasić, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1983
Intratumoral BCG and Corynebacterium parvum therapy of canine mammary tumours before radical mastectomyA L Parodi, W Misdorp, J P Mialot, et al.
Cancer Immunology, Immunotherapy : CII|April 1, 1995
Biological response modifiers (BRM) as antigens. III. T cell lines specific for BRM kill tumor cells in a BRM-specific mannerS Ozaki, T Okazaki, K Nakao
Cancer Immunology, Immunotherapy : CII|October 1, 1996
Anti-idiotype cancer vaccines: past and futureD Herlyn, R Somasundaram, W Li, et al.
Cancer Immunology, Immunotherapy : CII|October 1, 1996
Immune response against medullary thyroid carcinoma (MTC) induced by parental and/or interleukin-2-secreting MTC cells in a rat model of human familial medullary thyroid carcinomaS Lausson, B Fournes, C Borrel, et al.
Cancer Immunology, Immunotherapy : CII|October 26, 2018
Stromal interleukin-33 promotes regulatory T cell-mediated immunosuppression in head and neck squamous cell carcinoma and correlates with poor prognosisYi-Hui Wen, Han-Qing Lin, Hang Li, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1988
Indomethacin stimulation of macrophage cytostasis against MOPC-315 tumor cells is inhibited by both prostaglandin E2 and nordihydroguaiaretic acid, a lipoxygenase inhibitorG R Elliott, C Tak, C Pellens, et al.
Cancer Immunology, Immunotherapy : CII|November 14, 2016
Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case seriesLavinia Spain, Gerard Walls, Christina Messiou, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Characterization of T-lymphocyte subpopulations infiltrating primary breast cancerR Bilik, C Mor, B Hazaz, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1989
A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanomaA Lindemann, K Höffken, R E Schmidt, et al.
Pageof 650